Why the study?
Type 2 diabetes mellitus and heart failure are highly comorbid, warranting an examination of the mechanisms of action of SGLT2 inhibitors in these patients.
Do sodium-glucose cotransporter 2 inhibitors improve heart function and clinical outcomes in patients with type 2 diabetes mellitus and heart failure?
Do sodium-glucose cotransporter 2 inhibitors improve heart function and clinical outcomes in patients with type 2 diabetes mellitus and heart failure?
Answers are grounded in this paper and cite their sources.
SGLT2 inhibitors provide cardiovascular benefits in patients with comorbid T2DM and heart failure through multiple pleiotropic mechanisms beyond glycemic control.
on the mechanisms of action of sodium-glucose cotransporter 2 inhibitors (SGLT2i) in patients with type 2 diabetes mellitus (T2DM) and heart failure (HF). T2DM and HF are highly comorbid, with a significantly increased prevalence of HF in patients with T2DM. SGLT2i exhibit potential in reducing hospitalization rates for HF and cardiovascular mortality through multiple mechanisms, including improving blood glucose control, promoting urinary sodium excretion, reducing sympathetic nervous system activity, lowering both preload and afterload on the heart, alleviating inflammation and oxidative stress, enhancing endothelial function, improving myocardial energy metabolism, and stabilizing cardiac ion homeostasis. Further research and clinical practice will help optimize the use of SGLT2i in HF patients.
No takes yet. Share an insight, caveat, or question.
Zhang et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: